PPI prophylaxis didn't affect 90-day mortality rates among ICU patients | ACP Gastroenterology Monthly
Gastrointestinal bleeds were less common among at-risk ICU patients who received IV pantoprazole instead of placebo, but rates of clinically important events were similar overall.
Clinical prediction model may help determine management for acute lower GI bleeding | ACP Gastroenterology Monthly
Factors associated with safe discharge in the development and validation cohorts were age, female sex, no previous admission for lower GI bleeding, no blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin level.
Misoprostol may help treat obscure GI bleeding in patients taking aspirin, NSAIDs | ACP Gastroenterology Monthly
Complete healing of small-bowel ulcers and erosions, as assessed by video-capsule endoscopy, was significantly more common among patients receiving misoprostol than those randomized to placebo, a small British study found.
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
This month's quiz asks readers to determine the most appropriate next step in management for a 55-year-old man with a 2-day history of mild nausea and dyspepsia that is worse with fasting and improved with eating.
A 30-year-old woman is evaluated for a 2-month history of diarrhea with three to five loose stools per day.
MKSAP quiz: Medication management for joint pain due to degenerative disease | ACP Gastroenterology Monthly
This month's quiz asks readers to evaluate medication management in a 67-year-old woman with a history of pain related to degenerative joint disease that is well controlled with diclofenac.
Myocardial infarction risk appeared no greater with proton-pump inhibitors (PPIs) than with histamine H2 receptor antagonists in one recent study, while another study looked at the effect of a trainee-led program on inappropriate PPI infusions in
GI bleeding less common in U.S. veterans on NOACs than those on warfarin | ACP Gastroenterology Monthly
Significant bleeding occurred in 2.5% of the patients on warfarin and 0.6% of the patients on non-vitamin K antagonist oral anticoagulants (NOACs).